Scientific MOOCs follower. Author of Airpocalypse, a techno-medical thriller (Out Summer 2017)

Welcome to the digital era of biology (and to this modest blog I started in early 2005).

To cure many diseases, like cancer or cystic fibrosis, we will need to target genes (mutations, for ex.), not organs! I am convinced that the future of replacement medicine (organ transplant) is genomics (the science of the human genome). In 10 years we will be replacing (modifying) genes; not organs!

Anticipating the $100 genome era and the P4™ medicine revolution. P4 Medicine (Predictive, Personalized, Preventive, & Participatory): Catalyzing a Revolution from Reactive to Proactive Medicine.

I am an early adopter of scientific MOOCs. I've earned myself four MIT digital diplomas: 7.00x, 7.28x1, 7.28.x2 and 7QBWx. Instructor of 7.00x: Eric Lander PhD.

Upcoming books: Airpocalypse, a medical thriller (action taking place in Beijing) 2017; Jesus CRISPR Superstar, a sci-fi -- French title: La Passion du CRISPR (2018).

I love Genomics. Would you rather donate your data, or... your vital organs? Imagine all the people sharing their data...

Audio files on this blog are Windows files ; if you have a Mac, you might want to use VLC ( to read them.

Concernant les fichiers son ou audio (audio files) sur ce blog : ce sont des fichiers Windows ; pour les lire sur Mac, il faut les ouvrir avec VLC (

Regenerative meds market to soar

"Japan’s regenerative medicine market will total ¥1.6 trillion in 2030, up from ¥26 billion in 2012, with products made from human cells increasing in variety and the commercialization of those from artificially derived multipurpose stem cells, the industry ministry forecast Friday.
The Ministry of Economy, Trade and Industry hopes the estimate will encourage investment in the field, which has drawn attention in Japan after Kyoto University professor Shinya Yamanaka won the Nobel Prize last year for his advanced research on induced pluripotent stem (iPS) cells that can develop into any type of body tissue.
The estimate took into account the number of potential patients in the country and the per capita cost of such treatment.
Globally, the ministry projected that the market will grow to ¥17 trillion in 2030, compared with ¥340 billion last year.
The ministry also said the cost of clinical trials for regenerative medicine products may be reduced by some 60 percent and that production outlays could be slashed by around 20 percent, providing regulatory reforms are introduced to enable authorities to approve products in clinical trials more swiftly, a process that at present takes about seven years." (Source)


Aucun commentaire: